The recent draft Health Technology Assessment (HTA) methods report released by the Health Economics Methods Advisory group makes it crystal clear – policy grounded in conventional HTA methods (like the QALY) are willing to harm the individual for the sake of the formula-derived average.
The Data Mine: Upcoming ICER Report Uses an Unreliable Protocol Relying on Discriminatory Measures9/24/2025
By any measure, the methods behind ICER’s new report are bad for U.S. consumers, patients, and people with disabilities. Our newest "Data Mine" blog overviews the biggest potential problems to watch out for in this upcoming report.
As policymakers renew interest in referencing foreign drug prices, like Most Favored Nation proposals, how widely could this shift the U.S. to reliance on QALYs in its health care decision-making?
The Data Mine: Value Assessment Organizations Should Learn from the Experts on Patient Engagement6/3/2020
Dr. Steven Pearson, founder and president of the Institute for Clinical and Economic Review (ICER), recently wrote that no clear framework exists to engage patients in medical research. In A proposed framework for patient engagement throughout the broader research enterprise, published in the Journal of Comparative Effectiveness Research, Dr. Pearson acknowledges that patient engagement is an important component of medical research, but he fails to recognize years of accomplishments in the field. This misleading premise ignores rigorous patient-centered outcomes research and evolving development of evidence-based frameworks for patient engagement.
On Jan. 31, the Institute for Clinical and Economic Review (ICER) released its final revisions to its value assessment framework. The document describes changes in ICER’s process, including creating a formal process for incorporating new evidence that emerges after the assessment, standardizing cost-effectiveness thresholds across reviews, and increasing the incorporation of real-world evidence.
The National Council on Disability (NCD)’s report to President Donald Trump on Quality-Adjusted Life Years and the Devaluation of Life with a Disability provides a timely understanding and perspective of the implications of QALYs. This report will be an essential tool for advocates, coming from an independent, nonpartisan federal agency charged with advising the President, Congress, and other federal agencies regarding policies, programs, practices, and procedures that affect people with disabilities.
 The Institute for Clinical and Economic Review (ICER) recently assessed two treatments for spinal muscular atrophy (SMA), a rare and deadly genetic condition impacting 1 in 11,000 newborns each year.[1] In the absence of therapy intervention, death or the need for constant ventilation to breathe before the age of two years is the outcome for more than 90% of individuals diagnosed with SMA Type 1. SMA is the number one genetic cause of death for infants.
|
